Nanjing Well Pharmaceutical Group Co.,Ltd.
SHH: 603351.SS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Renrong Wu
- Employees
- 711
- Headquarters
- Nanjing, China
- IPO year
- 2019
- Market cap
- CN¥3.7B
- Website
- https://www.well-js.com
Loading 603351…
Loading profile data…Frequently asked questions about 603351
What does Nanjing Well Pharmaceutical Group Co.,Ltd. (603351.SS) do?
Nanjing Well Pharmaceutical Group Co.,Ltd. focuses on the research and development, production, and sale of pharmaceutical auxiliary materials in China. Its pharmaceutical materials include excipients for injectables and non-injectables. The company also provides synthetic base oils, such as hydraulic fluids, lubricity additives for metals, meta...
Where does 603351.SS trade?
Nanjing Well Pharmaceutical Group Co.,Ltd. (603351.SS) trades on the Shanghai Stock Exchange.
What sector is 603351.SS in?
Nanjing Well Pharmaceutical Group Co.,Ltd. (603351.SS) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Nanjing Well Pharmaceutical Group Co.,Ltd.?
Renrong Wu is the chief executive officer of Nanjing Well Pharmaceutical Group Co.,Ltd. (603351.SS).
Where is Nanjing Well Pharmaceutical Group Co.,Ltd. headquartered?
Nanjing Well Pharmaceutical Group Co.,Ltd. is headquartered in China.
Does 603351.SS pay a dividend?
Yes — Nanjing Well Pharmaceutical Group Co.,Ltd. (603351.SS) paid a trailing twelve-month dividend of CNY 0.40 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 603351.SS go public?
Nanjing Well Pharmaceutical Group Co.,Ltd. (603351.SS) completed its initial public offering in 2019.